SOHM Inc (PK) (SHMN) Quote

Yep, appears they are Restricted.

Held at DTC is unchanged.

https://www.otcmarkets.com/stock/SHMN/security

___
HL.

Outstanding shares increased.

SHMN ? Pink Current

🔑 AS:3.00B ? OS:1.91B ? R:639.29M ? UR:1.27B ? DTC:1.26B

✨ Outstanding Shares Updated:
- 🔴 From: 1,600,576,407 (1.60B)
- 🟢 To: 1,910,576,407 (1.91B - 6/18/2024)
(Diff: 310.00M, % Change: 19.368%)

Aguilar and ABBIE will leave if SHMN can't pay the millions promised for it in a few months. Breach of contract

SHMN was lucky to have him as long as they did imo......

we don't get to see the behind the scenes day by day, hopefully he made a difference going forward, I won't comment on his impact on the labs, one has to wonder what is going on with SD, so far it's been very disappointing.

Thanks. Actually he used to work at Quidel full-time back in 2013-2019.

So now he's back there doing some contract work for them. His work for Sohm has no doubt been invaluable. It's like you've said before too, we all know what we're waiting for, and in my opinion, it's going to be big green candles at some point. :)

https://www.linkedin.com/in/wm-dewey-rushing-7505a95/details/experience/

hL

great DD hl, thanks....

not sure what you read that made you assume it was an " unfriendly " departure...

and this comment, is it a joke ?

Don't see Aguilar leaving with out taking ABBIE with him.

He has now moved on to QuidelOrtho. He apparently fulfilled his tasks for Sohm, but according to his LinkedIn, he has been doing double duty for them since March 2023, and he left Sohm as of this month. He's always been an Independent guy, probably makes good money as a contractor/consultant.

Sad to see him go, but I appreciate your balanced comments. Hoping everyone still involved has learned a thing or two from him that can be continued, and if he needs replaced, they do it soon. According to their Tweet, they are still building their team, so maybe Aguilar already is in the middle of that process. Maybe we'll see an announcement at some point.

https://www.linkedin.com/in/wm-dewey-rushing-7505a95/

https://www.linkedin.com/company/quidelortho/

HL. Upsart Biotech at .0011.

Certainly does appear like a unfriendly departure.

SOHM, Inc.
@sohminc
Today we announce that Mr. Dewey Rushing's resignation has been accepted and relieved from his consulting assignment and as a VP-Quality with immediate effects. We are continuing to build our quality team to match our expected growth and vision.

But you know it could be as simple as a difference of Dewey thought he was worth X amount of dollars and Barry thought otherwise.

Don't see Aguilar leaving with out taking ABBIE with him.

But you are correct the wrong officer resigned.

Really doesn't matter , if there is any real money that going to be made here it is with ABBIE not the other part of the business.

$SHMN: Sad...But Reality setting in here (for me too)!

1. Dewey resignation is a harbinger of things to come!
The man is a Consummate Professional (& simply couldn't have been Fired....WHY? B/C there's NOTHING for him to do)!

2. There are NO Pharma MFG lines, nor Two 'F'-KNG Facilities! Prove it Barron! Upload AUTHENTIC VIDEOS!

3. Who's next? Aguilar or Gallegos ? ...(& the other two Nobody knows WTF they're upto )!.

4. Aguilar is putting his signature on Barry's BS Tweets & PRs.
He'll be in a lot of trouble, when looking for work in Biotech Bay / Silicon Valley.
You can bet on that!

5. Even if this was ONLY about ABBIE Kits....the company needs a certified Q/A V.P. or Dir on employ.
So ABBIE kits shipping in Q3 is HIGHLY UNLIKELY W/0 any Quality Control.
Unless they're outsourcing Q/A (Which will take a couple of months to get the Metrics ironed out)!

So best case Q4-Q1-2025
And the "Thousands of ABBIE Kits & $M'". ..
If TRUE....Q3-2025 -Q4 2025!

Get Barron FIRED! ASAP to SAVE this Co!

Today we announce that Mr. Dewey Rushing's resignation has been accepted and relieved from his consulting assignment and as a VP-Quality with immediate effects. We are continuing to build our quality team to match our expected growth and vision.— SOHM, Inc. (@sohminc) June 17, 2024


Bummer.

HL. Baby pharma, upstart biotech at .0011. $shmn

Yes! Merge with NVDA

they only need one thing now, and we all know what that is....

They have nothing but tweets.. and 50k Qs

This is an excellent example of how a coherent media strategy can drive interest and volume, if not necessarily PPS (at least, not immediately).

Given that this ticker frequently goes days at a time with no to nominal shares traded, a "significant" bump in share price from a $100 trade is meaningless when there is no follow-up...nobody can capitalize on it. IMHO, we need volume first, PPS second. Putting out good news without bullshit revenue projections that the market immediately discounts goes a long way toward that goal.

Bravo, SHMN. Bravo.

sure does knife...

SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-cell immunotherapy from a Healthy Human Donor

CHINO HILLS, CA / ACCESSWIRE / June 10, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnology company that manufactures and markets generic drugs covering numerous treatment categories, announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T -Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This breakthrough method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. "The preliminary data is intriguing and suggests ABBIE can be used as a powerful tool in the development of immunotherapies."-David Aguilar Ph.D. COO SOHM Inc.

Dr. Aguilar, further stated that, CAR T-cell therapy is a groundbreaking form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells.

The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options.

The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer.

In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses.

On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells.

In terms of the market value for CAR T companies, According to Vision Research Reports, the global cancer immunotherapy market size was estimated at USD 125.73 billion in 2023 and it is projected to increase USD 280.11 billion by 2033 with a CAGR of 8.34% from 2024 to 2033. Some of the key players in the CAR T-cell therapy market include Novartis, Gilead Sciences (through its acquisition of Kite Pharma), and Bristol Myers Squibb (through its acquisition of Celgene).

Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.

We are proud to announce ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. ABBIE has the potential to revolutionize genome editing by allowing precise and targeted integration of predesigned donor DNA into the genome of cells. This groundbreaking technology opens up new possibilities for treating genetic diseases, developing novel therapies, and advancing scientific research. With its advanced targeting system, simplified operational protocols, and reduced risk of off-target effects, ABBIE could well become the gold standard for genetic modifications, paving the way for new discoveries and treatments said David Aguilar, COO of SOHM, Inc.

For more information about SOHM Inc. and its work on ABBIE, please visit www.SOHM.com

https://www.accesswire.com/873681/sohm-inc-announces-its-abbie-genome-editing-technology-successfully-engineered-a-t-cell-immunotherapy-from-a-healthy-human-donor

News out, looks promising.

https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announces-its-ABBIE-Genome-Editing-Technology-Successfully-Engineered-a-T-cell-immunotherapy-from-a-Healthy-Hum?id=443403

All the best,

Knife

A million in Q3.... LOL

Booked is a cop out. There is no way to know if they actually have that. They've had other big orders "booked" before and nothing happened in the financials.

They are going to have to produce, market, and sell alot of kits in a short amount of time for revenues to jump in any meaningful way. Where are the resources to do that?

Another huge advantage CRISPR has over alternative gene-editing techniques is its expense. While previous techniques might cost a laboratory upward of $500 to edit a single gene, a CRISPR kit can do the same thing for under $100.

I've bought more than a few shares!!! Lol

always with the negative spin, yes, most of us know that the 4th qtr comes out with the annual due 3/31.

here's an alternative spin if you will, they most likely are making kits as we speak, imo all they need to do is announce orders booked in q3, along with shipping lets say at least a million in rev, booked in q3. personally I would expect much more but not fully knowing the cost of the kits we would all be guessing.

Then we have the Licensing deals that could hit at any time, along with this..

The company has other types of kits and related products in development.

https://www.globenewswire.com/news-release/2024/05/22/2886768/0/en/SOHM-Inc-Targets-Revolutionary-New-ABBIE-Genome-Editing-Kits-for-Q3-2024.html

so bash away....

June 4th. 2024. How are we looking?

If what they say is true, Q3 starts in less than a month. They'd have to make these kits in some kind of quantity, market them, and get them shipped out. So realistically, it would be Q4 before they'd hit the financials, which puts all the way until April.

Maybe one of their two manufacturing facilities can produce something more than dust. The San Diego one has been getting ramped up for over a year now.

buy a few kits Mike and get the ball rolling !!!!!!

lol...

it's hard to tell what he meant, including Dec 15th.....

what is truely pathetic is when a post like that goes without push back by the so called shareholders here, and correction by the author.

and not the first time..

I agree with your thoughts here JD, and as I have said all along ABBIE doesn't " feel " like anything they have bombed on before, at least to me. I think you know what I mean...

It kinda feels like their last opportunity to restore investor confidence.

Very fair...I can't argue with that...

I suspect he meant Q3.

I remain hopeful that ABBIE will indeed be the spark that SHMN needs. I just hope that they can deliver.

By laying out a timeframe for revenue generation, they are either positioning themselves for success, or for a repeat of various other "blockbusters" that were announced and then allowed to fade away without an appreciable impact on revenue.

It kinda feels like their last opportunity to restore investor confidence.

from the first announcement of the acquisition of ABBIE...

Revenue generations can be obtained immediately through licensing and gene-editing kits slated to be released for commercialization in 3Q/4Q 2024

https://www.globenewswire.com/en/news-release/2023/09/26/2749662/0/en/SOHM-Announces-Its-Acquisition-of-ABBIE-a-World-Class-Gene-Editing-Platform-Which-Can-Deliver-Genetic-Payloads-Using-Non-Viral-Vectors.html

the last PR ON 5/22/2024

SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024

https://www.globenewswire.com/news-release/2024/05/22/2886768/0/en/SOHM-Inc-Targets-Revolutionary-New-ABBIE-Genome-Editing-Kits-for-Q3-2024.html


Not sure what Dec 15th has to do with anything, maybe you can clarify...

Now that the A-Hole Barron has quietly PUNTED all the way to Dec 15th!

this is also confusing, 1000's of kits when Q2 fins are disclosed ?

(When Q-2: Fins are disclosed)
1000's of Kits & $M's will be mostly HOT AIR!

still scratching my head on the guy/gal who dumped 8ml @.0009 the other day...

just seemed like bad timing, guess we'll find out eventually..

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174451837

$SHMN: P2D: Be careful what you say...
It's beginning to look like a TURD!

And for me to say AFTER all these years...is eye opening!
We'll see...Now that the A-Hole Barron has quietly PUNTED all the way to Dec 15th!

(When Q-2: Fins are disclosed)
1000's of Kits & $M's will be mostly HOT AIR!
Whatever happened to the Facility?

The Leadership needs to CHANGE here. Period!
Last Post until Dec.

Low floater!

Nice volume today. Did I miss a update

Fuze got lit here? 28M shares +44%.

$SHMN Added .0009 for a swing yesterday.
Had nice news recently that went under the radar plus Pharma tickers are hot RN.$RSPI $PPCB pic.twitter.com/ERodYv7cYN— lumina!re (@PredatorOTC) May 30, 2024

Nice!

This company claims they can edit genes, they can't even properly edit a tweet or website.

Amazing insight. Next up: you'll be pointing out the significance of Oxford Commas.

Dude, we get it. You have a vested interest in this stock going down. But you're really screaming into an echo chamber here. Give it a rest.

$SHMN: MDP: You're proving to be an Invaluable "Proof-Reader"...

Thanks for bringing this to our attention.

This is GREAT NEWS!
It shows that there's a Probability of using other types of Gene Editing Tech [Using an Enzyme is ONE type...they are others]
So the USAGE of the word "Editor", implies that they've BROADENED the SCOPE, as some Nucleases may/may NOT be referred to as Enzymes [all this assuming that Barry didn't Copy n' Paste from somewhere...If so...further proof that a Soap-Seller can't be an Advanced Bio-Tech CEO]
ABBIE is "Binding BASED", as are all 👇️THREE Current Technologies in R&D
*********************************************************************************************************************
👇️Reference:- Genome-Editing Technologies: Principles
and Applications
Thomas Gaj,1,4 Shannon J. Sirk,2 Sai-lan Shui,3 and Jia Liu3,4


Here we review three foundational technologies—clustered regularly interspaced
short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9), transcription activator-like effector nucleases (TALENs), and zinc-finger nucleases (ZFNs).
**************************************************************************************************************************

They can't even be consistent on what ABBIE means.

From today's tweet : ABBIE (A Binding Based Integrase Editor)
https://x.com/sohminc/status/1794014004030972296/photo/1

From their website and every other mention: ABBIE (A Binding Based Integrase Enzyme)
https://sohm.com/abbie-systems/

How many times can you put "potential", "possible", and "expected" in one PR? SHMN going for the record with that one today for sure...

Q3 starts on July 1......

this could be a moonshot, posters can scoff all they want, my belief in ABBIE is unwavering, and has been since SHMN acquired it.

The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in Q3. This has been possible due to our committed, consistent and focused approach by our lead scientists at our lab at UACI in Tucson, AZ.

Interesting: "...and upstart biotechnology company."

Don't remember them saying that before...

Baby Pharma and Upstart Biotech for the trips?

Please bring the Big Green Candles. hL shmn

May 22, 2024 12:57 ET SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024

https://www.globenewswire.com/news-release/2024/05/22/2886768/0/en/SOHM-Inc-Targets-Revolutionary-New-ABBIE-Genome-Editing-Kits-for-Q3-2024.html

$SHMN: MDP: Did it occur to you that they DON'T need to?

Looks like they've generated ENOUGH LEADS from AACR-24.

At this Point in time all they [$SHMN] needs is to PR ONE/TWO Bio-Tech Companies that
they're working with. And the PPS will FLY. In any case it's a Forward Looking Statement, get permission
from ONE/TWO companies & PR...Get moving Barry & Tony!
Coastar doesn't COUNT...SOMEBODY BIGGER!


And you my friend will be in HOT WATER! Better COVER!👇️

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174461650

Years of hype and pump no longer works when nothing material comes of it. Thanks to today's PR I no longer have a position here. High trading fees for OTC pennies doesn't help either.

PPS, and perhaps more importantly, volume. I was (optimistically; foolishly) hoping that we'd see a meaningful improvement in both. The lack of reaction would seem to underscore the notion that folks just don't trust SHMN to follow through on their forward looking statements. The disappointing Q1 numbers after all of the upbeat reports about manufacturing capacity would seem to validate this distrust.

It really does feel like the Company is betting the farm on ABBIE. Hope they're right.

Hey JD, by lack of response I'm assuming you mean share price ? imo demonstration of ABBIE being monetized is months away, I do agree the public, mainly pink sheet traders doesn't believe it....time will tell..

Revenue generations can be obtained immediately through licensing and gene-editing kits slated to be released for commercialization in 3Q/4Q 2024

https://www.globenewswire.com/news-release/2023/09/26/2749662/0/en/SOHM-Announces-Its-Acquisition-of-ABBIE-a-World-Class-Gene-Editing-Platform-Which-Can-Deliver-Genetic-Payloads-Using-Non-Viral-Vectors.html

They didn't even go to the Synbiobeta conference like they said they would.

$SHMN:SLC: The problem is the Leadership...the "Honorable" DEI-Hire Barron...

He's tweeting👇️ like a 80's /90's Soap Salesman. It hasn't worked for TWO years and he's still
going on! Talk about a DEI-Hire! What a D-A$$! "Overwhelming Interest & Impact"? Impact in business, has a Monetary METRIC Attached!
Where is it? MORON!
Tweet this way AFTER at least ONE P.O or Licensing agreement [anything that SHOWS $ coming in to $SHMN] NOT ahead of time and then fall flat on your
foolishness
Consult someone who has REAL EXPERIENCE in Corporate & Business Communications! Not AVON lip sticks & Amway Soap!
We’re thrilled to announce that our presentation at #AACR was met with an exceptional reception. It was an honor to showcase our technology to esteemed researchers and leaders in the biotech industry.

The overwhelming interest and impact generated by our innovation have been… pic.twitter.com/50Ggv6hqPj— SOHM, Inc. (@sohminc) April 9, 2024

The lack of response from the AACR preso supports this 100%...unless/until they demonstrate that ABBIE can be monetized, the market doesn't trust SHMN enough to move based on news.